Intracranial B7-H3 CAR-T Shows Early Promise in Recurrent Glioblastoma
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Zhang Y, Chi X, Feng R, et al.
Aug 7, 2026 · Published in: Nature Medicine
CAR-T cell therapy offers new hope for recurrent glioblastoma.
Comparative Safety Signals for Melanoma Checkpoint Inhibitors Across Trials and FAERS
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Chen Y, Liang X, Chen X, et al.
Jul 29, 2026 · Published in: Health Science Reports
Immune checkpoint inhibitors in melanoma: safety profiles unveiled.
Venetoclax TDM Reduces Toxicity Risk in Posaconazole-Treated AML Patients
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Sani B, Cignetti A, Leporati M, et al.
Jul 25, 2026 · Published in: Oncology Research
Venetoclax levels spike with posaconazole: TDM is essential.
Immunotherapy May Enable Safe Axillary De-escalation in Node-Positive TNBC
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Li Z, Qu Z, Pei S, et al.
Jul 23, 2026 · Published in: Frontiers in Immunology
Chemo-immunotherapy may enable less invasive breast cancer surgeries.
Two-Year Lenalidomide Maintenance Matches Indefinite Therapy in Standard-Risk Myeloma
Analysis Oncology Pharmacy Practice-changing Grade: Moderate
Kumar S, Jacobus S, Cohen A, et al.
Jul 16, 2026 · Published in: N Engl J Med
Two-year lenalidomide is as effective as indefinite therapy in multiple myeloma.
Adjuvant TACE and Lenvatinib-Tislelizumab Show Comparable Post-Resection Benefit
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Feng X, Ao Y, Wang L, et al.
Jul 14, 2026 · Published in: Frontiers in Immunology
Adjuvant therapies improve survival in high-risk liver cancer patients.
Immune Checkpoint Inhibitors Redefine First-Line Cholangiocarcinoma Therapy
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Nisa FU, Ali M, Khan T, et al.
Jul 6, 2026 · Published in: Journal of the Egyptian National Cancer Institute
Immune checkpoint inhibitors redefine advanced cholangiocarcinoma treatment.
Targeted Therapy Evolution: From Kinase Inhibitors to Protein Degraders
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Jun 27, 2026 · Published in: Critical Reviews in Oncology/hematology
Targeted cancer therapies revolutionize personalized oncology treatment.
Variant-Stratified ALK Inhibitor Selection in EML4-ALK Lung Cancer
Analysis Oncology Pharmacy Confirmatory Grade: Low
Li S, Bao L, Zhou D, et al.
Jun 26, 2026 · Published in: Technology in Cancer Research & Treatment
EML4-ALK fusion: A precision target in NSCLC fraught with resistance challenges.
Sequencing Systemic Therapy in Resectable NSCLC: Equipoise Remains
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Osarogiagbon RU, Cetnar JP, Aljumaily R
Jun 23, 2026 · Published in: American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
New trials may refine lung cancer therapy timing strategies.
KDIGO Consensus Reframes Kidney-Heart Failure Comanagement Priorities
Analysis Oncology Pharmacy Confirmatory Grade: Low
Izzedine H, Perazella MA, Kuruvada KM, et al.
Jun 20, 2026 · Published in: Kidney International
Preventing kidney damage in cancer treatment requires proactive strategies.
Venetoclax Combinations Redefine Chemotherapy-Free CLL Treatment Paradigms
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Kegyes D, Muresan X, Bancos A, et al.
Jun 11, 2026 · Published in: Critical Reviews in Oncology/hematology
Venetoclax brings new promise to chronic lymphocytic leukemia management.
Atezolizumab Plus FOLFOX Halves Recurrence in dMMR Stage III Colon Cancer
Analysis Oncology Pharmacy Practice-changing Grade: High
Sinicrope FA, Ou FS, Arnold D, et al.
Mar 26, 2026 · Published in: N Engl J Med
Atezolizumab enhances survival in dMMR colon cancer.
Biomarker Strategies for Chemotherapy Cardiotoxicity: Promise Versus Validation
Analysis Oncology Pharmacy Confirmatory Grade: Very Low
Kong Y, He R, He H, et al.
Feb 25, 2026 · Published in: Rev Cardiovasc Med
New biomarkers offer promise for early detection of chemotherapy-induced heart damage.
Dual PD-L1/Galectin-9 CRISPR nanoparticles curb melanoma in mice
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Fang T, Deng Y, Chen M, et al.
Jun 6, 2025 · Published in: Biomaterials
CRISPR-loaded nanoparticles boost immune response against cancer.